Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage… EP News Bureau Oct 30, 2025 Phase IIa data show faster infection resolution and shorter hospital stays when AP-SA02 is added to standard antibiotic therapy,…
Basilea’s Zevtera will play unique yet critical role in MRSAB: GlobalData EP News Bureau Apr 15, 2024 It is the first new therapy to gain FDA approval in over 15 years
